RxDoctor Payments Data

Lucia Avany, MD

Family Medicine · Brooklyn, NYNPI 1538320494

Payments from drug & device makers

$10,344in general payments, 2019–2025

Across 516 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • GSK$631
  • AstraZeneca$602
  • Amarin Pharma, Inc.$452
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$10,311100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,344 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$164,447
Medicare patients
265
Services billed
2,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,032$364,529
ZenpepLipase/Protease/Amylase225$306,426
Diclofenac Sodium413$295,083
EliquisApixaban360$221,737
ZtlidoLidocaine363$169,288
MounjaroTirzepatide148$160,518
Repatha SureclickEvolocumab293$158,708
CreonLipase/Protease/Amylase105$156,810
LinzessLinaclotide254$138,546
OzempicSemaglutide124$114,795
TrulicityDulaglutide107$108,040
TradjentaLinagliptin184$101,830
XifaxanRifaximin36$83,391
JanumetSitagliptin Phos/Metformin Hcl130$78,208
JanuviaSitagliptin Phosphate129$75,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Ubrelvy, Namzaric$2,207$378,395443 claims
Aimmune Therapeutics, Inc.Zenpep$214$306,426225 claims
Lilly USA, LLCMounjaro, Trulicity$275$268,558255 claims
PfizerEliquis, Nurtec Odt$261$244,258378 claims
Scilex Pharmaceuticals Inc.Ztlido$286$169,288363 claims
MerckJanumet, Januvia, Janumet Xr$30$167,150283 claims
Boehringer IngelheimTradjenta, Jardiance$160$144,742253 claims
AmgenProlia, Otezla$1,968$117,21751 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,161$115,59897 claims
Novo NordiskOzempic$340$114,795124 claims
AstraZenecaFarxiga$602$55,40997 claims
NovartisEntresto$210$45,10864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →